|
|
Article: Salix Pharmaceuticals Acquires U.S. Right to Lupin's Proprietary Bioadhesive Technology for Extended Release Rifaximin Product.
- Article from:
- Journal of India
- Article date:
- October 20, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin's proprietary technology. In connection with this agreement, Salix and Lupin have entered into an exclusive agreement in the United States for supply of rifaximin active pharmaceutical ingredient (API). Salix is required to make a ...
Related newspaper, magazine, and journal articles:
|
|
Article: Salix Pharmaceuticals, Ltd. - Financial and ...
M2 Presswire;
May 3, 2009 ;
700+ words
... ... companiesandmarkets.com: Salix Pharmaceuticals, Ltd. - Financial and ... com adds new report: Salix Pharmaceuticals, Ltd. - Financial and Strategic Analysis Review Salix Pharmaceuticals, Ltd. - Financial and ...
|
|